Novartis Egypt
- Company typePrivate
- Founded1996
- HeadquartersEgypt, Egypt
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
Novartis Egypt firmographics
Firmographics- Name
- Novartis Egypt
- Legal name
- Novartis Egypt
- Website
- https://novartis.com.eg
- Company type
- Private
- Founded year
- 1996
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Ownership category
- akta.pro rank
Where Novartis Egypt is headquartered
LocationHeadquarters
- HQ city
- Egypt
- HQ country
- Egypt
- HQ region
- Africa
Offices1 record
Markets served
Novartis Egypt business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations
Distribution channels2 records
Marketing channels3 records
Novartis Egypt product offering
Product offeringCore offering
Novartis Egypt is a subsidiary of Novartis AG that develops, markets, and distributes innovative pharmaceutical medicines in Egypt across therapeutic areas including oncology, immunology, and specialty medicines. The company supports its marketed product portfolio with an ongoing clinical pipeline of investigational therapies and engages with healthcare professionals and patients through patient-centric programs and disease information resources.
Product overview
Novartis Egypt operates as a subsidiary of the global Novartis AG pharmaceutical company, which was created in 1996 through a merger of Ciba-Geigy and Sandoz. The company's product portfolio centers on innovative medicines and includes the Novartis Clinical Pipeline for investigational therapies, the Novartis Product Portfolio for marketed products, the Patient Commitment Program focused on patient collaboration, and the COVID-19 Information Center. The organization focuses on discovering and developing breakthrough treatments across therapeutic areas including oncology, immunology, and specialty medicines, with operations spanning healthcare professionals, patients, ESG initiatives, and career opportunities.
Differentiator
Problem solved
Functional benefit
Products and services
- Novartis Clinical Pipeline A comprehensive view of Novartis's drug development pipeline, showcasing investigational therapies and clinical trials across various therapeutic areas; serves as the source of future innovative medicines offered by Novartis Egypt.
- Novartis Product Portfolio An overview of Novartis's marketed products covering innovative medicines across multiple therapeutic areas including oncology, immunology, and specialty medicines; the core commercial offering distributed in Egypt through healthcare providers and pharmacies.
- Patient Commitment Program A patient-centered initiative focused on discovering new ways to improve and extend people's lives through collaboration with the global patient community; serves patients and caregivers in Egypt.
- COVID-19 Information Center A dedicated information resource providing COVID-19 related updates, guidance, and resources for patients and healthcare professionals in Egypt.
Companies that use Novartis Egypt
Customer profileSegments3 records
Ideal customer profiles2 records
Novartis Egypt technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Novartis Egypt partnerships and signals
Strategic signalScale indicators3 records
Recent moves4 records
Expansion highlights3 records
Novartis Egypt competitors and assessment
Company assessmentDirect peers
- Sanofi Egypt: Egyptian subsidiary of Sanofi, a global pharmaceutical major with presence across specialty care, vaccines, and general medicines. Comparable to Novartis Egypt in therapeutic-area breadth, distribution model, and multinational structure in Egypt.
- Bayer Egypt: Egyptian subsidiary of Bayer, a diversified multinational with pharmaceutical, consumer health, and crop science divisions. Comparable in Egypt-market presence, distribution scale, and therapeutic-area breadth to Novartis Egypt.
- MSD (Merck) Egypt: Egyptian subsidiary of MSD (Merck & Co.), a major multinational with strong oncology and vaccines franchises. Competes with Novartis Egypt in similar therapeutic areas and Egyptian institutional channels.
- GSK Egypt: Egyptian subsidiary of GlaxoSmithKline, a multinational pharma major with overlap in specialty medicines and vaccines. Comparable in scale, distribution model, and market positioning to Novartis Egypt in Egypt.
- AstraZeneca Egypt: Egyptian subsidiary of AstraZeneca, with strong overlap in oncology and specialty medicines. Competes with Novartis Egypt in similar HCP channels and faces the same Egypt-specific pricing and reimbursement dynamics.
- Roche Egypt: Egyptian subsidiary of Swiss multinational Roche, a direct peer in oncology and specialty innovative medicines. Competes head-to-head with Novartis Egypt in Egypt's premium-priced hospital channel, particularly in oncology biologics.
- AbbVie Egypt: Egyptian subsidiary of AbbVie, with direct overlap in immunology and specialty care. Comparable multinational structure, innovative-medicine portfolio focus, and Egyptian HCP engagement model.
- Pfizer Egypt: Egyptian subsidiary of Pfizer Inc., the largest global pharmaceutical company. Directly competes with Novartis Egypt in oncology, immunology, and specialty innovative medicines within the same Egyptian market using the same HCP-direct + pharmacy distribution model.
Emerging players
- EIPICO: Egyptian Pharmaceutical Industries Company, a leading local generic manufacturer. Comparable as an Egypt-headquartered pharma competitor but differentiated as a domestic generics producer vs. Novartis Egypt's premium innovative-medicine focus.
- Eva Pharma: One of Egypt's largest domestic pharmaceutical manufacturers with growing presence in branded generics and specialty medicines. Comparable as a competing Egypt-based pharma entity serving overlapping patient segments, though differentiated by local manufacturing vs. Novartis's imported innovative focus.
Market position
Weaknesses4 records
Competitive moat4 records
Key risks5 records
Key highlights5 records
Customer concentration
Novartis Egypt social profiles
Digital presenceNovartis Egypt financial estimates
Financial estimateRevenue estimate
Valuation estimate
Novartis Egypt leadership team
Management profileNumber of profiles
Novartis Egypt funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Novartis Egypt M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Novartis Egypt
What does Novartis Egypt do?
Novartis Egypt is a subsidiary of Novartis AG that develops, markets, and distributes innovative pharmaceutical medicines in Egypt across therapeutic areas including oncology, immunology, and specialty medicines. The company supports its marketed product portfolio with an ongoing clinical pipeline of investigational therapies and engages with healthcare professionals and patients through patient-centric programs and disease information resources.
Is Novartis Egypt a public or private company?
Novartis Egypt is a private company. It is classified as corporate owned and is currently operating.
When was Novartis Egypt founded?
Novartis Egypt was founded in 1996. It employs 101 to 250 people.
Where is Novartis Egypt based?
Novartis Egypt is headquartered in Egypt, Egypt, in the Africa region.
Who are Novartis Egypt's main competitors?
Direct peers on record are Sanofi Egypt, Bayer Egypt, MSD (Merck) Egypt, GSK Egypt, AstraZeneca Egypt, Roche Egypt, AbbVie Egypt and Pfizer Egypt. Emerging players are EIPICO and Eva Pharma.
Does Novartis Egypt have an API?
No public API is recorded for Novartis Egypt.